Key Drivers
- Margin expansion
- Strong liquidity
- Heavy intangibles
AIAI Summary
Hologic has shifted into a higher‑margin, women's‑health consumables business with strong free cash flow and improving margins, but that upside is largely priced in and requires execution to translate into further re‑rating. Investors should watch near‑term Diagnostics consumable trends, tariff relief, or accretive tuck‑ins as the specific catalysts that would justify the premium—otherwise modest revenue slips will quickly compress EPS given rich multiples.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin expansion
- •Strong liquidity
- •Heavy intangibles
Hologic shows improving profitability and strong free cash flow with expanding gross/EBITDA margins and ample liquidity, but carries rich valuation and large intangibles that reduce tangible equity.
Price Behavior
Key Price Behavior Insights:
- •Tight consolidation
- •Slight upside bias
- •Low volatility
Over the last month HOLX has traded in a tight ~$0.7 range, sitting slightly above its short-term average and pinned between support near $75.12 and resistance near $75.75—shallow upside but no breakout conviction.
Persistently narrow ~ $0.7 range over last month indicating muted momentum
Sentiment & News
Key News Insights:
- •Pending $76 buyout
- •Diagnostics mixed
- •GYN surgical strength
Hologic's $76 buyout and tariff-driven Diagnostics headwinds constrain near-term upside despite a 52-week high, strong GYN-surgical results and potential longer-term lifts from Panther Fusion, new assays and AI-driven Genius amid mixed institutional flows.
Near-term gains are capped by buyout dynamics and sector pressures, but women's-health leadership and pipeline innovations support medium-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings